Andere Sprachen SofWave Medical Ltd.

Aktien

A409GS

IL0011754392

SOFW

Markt geschlossen - TEL AVIV STOCK EXCHANGE Andere Börsenplätze 16:24:12 16.05.2024			% 5 Tage	% 1. Jan.
1 748 ^ILa	-2,46 %		-1,69 %	+27,41 %

09.05.	SofWave Medical Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
06.03.	SofWave Medical Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights	09.05.
SofWave Medical : Presentation- Q1 2024 Summary-May 2024	09.05.
SofWave Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Sofwave Medical to Participate in the Needham 23rd Annual Healthcare Conference	28.03.
Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	06.03.
SofWave Medical : Presentation- Investor Meeting-March 2024	06.03.
SofWave Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06.03.
Sofwave Medical to Present Pure Impact™ Strength and Muscle Toning Module’s First U.S. Industry Reveal at the 2024 American Academy of Dermatology (AAD) Annual Meeting	04.03.
Sofwave Medical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference	28.02.
Sofwave Medical Appoints Medical Aesthetics Industry Expert James Bartholomeusz to the Role of Chief Innovation Officer	12.02.
SofWave Medical Ltd. Appoints James Bartholomeusz as Chief Innovation Officer	12.02.
Sofwave Medical Receives 510(k) Marketing Clearance for Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology	03.01.
Sofwave Medical Receives 510(K) Marketing Clearance for Pure Impact Strength and Muscle Toning Body Module Utilizing Plyopulse EMS Technology	03.01.
Sofwave Medical Receives FDA Clearance of SUPERB™ Technology For Improvement of the Appearance of Skin Laxity on the Upper Arm	26.12.
SofWave Medical Ltd. Receives FDA Clearance of Superb?? Technology for Improvement of the Appearance of Skin Laxity on the Upper Arm	26.12.
Sofwave Earns Frost & Sullivan's 2023 North American Technology Innovation Leadership Award for Developing a Sophisticated Skin Tightening Ultrasound Technology with Minimal Downtime	20.11.
Sofwave Medical Reports Third Quarter 2023 Financial Results and Business Highlights	08.11.
SofWave Medical Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.
Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Treatment of Acne Scars	30.08.23
Sofwave Medical Announces FDA Clearance of SUPERB? Technology For Treatment of Acne Scars	30.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen SofWave Medical Ltd.

Aktien

A409GS

IL0011754392

SOFW

Andere Sprachen

Filter